Instituto Nacional de Medicina Genómica

What Instituto Nacional de Medicina Genómica does

Instituto Nacional de Medicina Genómica (INMEGEN) is Mexico's sole federal institute dedicated exclusively to genomic medicine, established in 2004 and operating under the Secretaría de Salud in Mexico City. It conducts genomics research, sequencing, bioinformatics analysis, and diagnostic services focused on the Mexican population, with an explicit mandate to address historical underrepresentation of Mexicans — including indigenous communities — in global genomic databases. Its portfolio spans the eVA early-detection program for hereditary breast and ovarian cancer (delivered via the eva.inmegen.gob.mx portal and in partnership with SEPI for indigenous outreach), the Laboratorio de Diagnóstico Genómico for clinical genomic testing, the Laboratorio de Identificación Humana for forensic genomics, the Unidad de Secuenciación for next-generation sequencing services, and a unique high-specialty postgraduate course in genomic medicine.

INMEGEN's technical stack combines Illumina and Oxford Nanopore sequencing platforms with proprietary bioinformatics pipelines for pathogen surveillance and for integrating clinical, biometric, and biochemical variables into early autism screening algorithms. The institute collaborates with national health institutes (INCAN, INPRFM, Hospital Juárez de México), federal entities (SEPI, PEMEX), international partners (Harvard Medical School / Joslin Diabetes Center, Universidad de Santiago de Chile, GA4GH), and industry (Pfizer research chair, Canifarma/Cofepris/Anafam triple-helix agreement). Recognition includes Nature Index 2025, GA4GH membership as the only Latin American institution, and the Carlos Slim Prize in Health 2026 awarded to Dra. Lorena Orozco.

As a federal public research institute, INMEGEN is funded through government budget allocations rather than commercial sales, and pricing details are not publicly disclosed. Its go-to-market is institutional rather than sales-led, distributing services through national health-system integration, indigenous-community outreach, academic collaborations, and an eVA self-serve web portal for cancer risk assessment. The institute reports 51-100 employees and operates primarily from a single Mexico City headquarters at Periférico Sur 4809, Tlalpan.

Name

Instituto Nacional de Medicina Genómica

Legal name

Instituto Nacional de Medicina Genómica

Website

https://inmegen.gob.mx

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

INMEGEN is Mexico's federal genomic medicine research institute under the Secretaría de Salud, delivering sequencing, bioinformatics, clinical diagnostics, forensic identification, and the eVA hereditary cancer early-detection program for Mexican populations including indigenous communities.

Ownership category

akta.pro rank

Product category

Genomic Medicine Research and Precision Healthcare Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Population Genomics & Preventive Precision Health Programs (HLAAANAL), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Genomic medicine research
• Precision medicine services
• Hereditary cancer screening
• Clinical genomic diagnostics
• Human identification genomics

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Government-funded research and public health services: As a public institution under Mexico's Secretariat of Health (Secretaría de Salud), INMEGEN is funded through federal government budgets for healthcare research, genomic testing services, and public health programs. Revenue comes from government allocations rather than commercial sales.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Instituto Nacional de Medicina Genómica (INMEGEN) is Mexico's federal public research institute that conducts genomic medicine research and delivers precision medicine services for the Mexican population. Its offerings include the eVA hereditary cancer risk assessment program, clinical genomic diagnostics through the Laboratorio de Diagnóstico Genómico, next-generation sequencing services via the Unidad de Secuenciación, forensic human identification services, and a unique postgraduate specialization in genomic medicine.

Product overview

Instituto Nacional de Medicina Genómica (INMEGEN) is Mexico's national genomic medicine research institute offering a portfolio of genomic health services. The core offerings include eVA (Estrategia de Vigilancia Anticipada) for hereditary cancer risk assessment, the Laboratorio de Diagnóstico Genómico for clinical genomic testing, and the Unidad de Secuenciación for next-generation sequencing services. The institute also operates a Human Identification Laboratory and provides academic training through its unique postgraduate course in genomic medicine. These services collectively support precision medicine applications for Mexican populations, including cancer prevention, metabolic disease research, and psychiatric genomics.

Differentiator

Problem solved

Functional benefit

Products and services

• eVA - Estrategia de Vigilancia Anticipada A comprehensive precision medicine strategy for early detection of genetic variants predisposing to hereditary cancer, providing genetic counseling and variant detection in genes associated with breast and ovarian cancer risk. Plans exist to expand coverage to metabolic, cardiovascular, and psychiatric conditions.
• Laboratorio de Diagnóstico Genómico (LDG) Genomic diagnostic laboratory offering tests for hereditary predisposition to breast and ovarian cancer, genetic risk evaluation, and clinical genomic services for prognosis, diagnosis, and disease monitoring.
• Laboratorio de Identificación Humana Forensic human identification laboratory using state-of-the-art genomic technology, serving as a scientific reference for identifying missing persons in Mexico in collaboration with federal government authorities.
• Unidad de Secuenciación (USec) Sequencing unit providing next-generation sequencing services, library preparation, and genomic data analysis training and workshops for institutional and external researchers.
• Talleres de Secuenciación de Nueva Generación Academic training workshops on next-generation sequencing library preparation and genomic data analysis, covering 16S metagenomics, target capture, and bioinformatics tools for researchers and students.
• Medicina de Precisión - Precision Medicine Services Precision medicine services using genomic information for cancer control, risk stratification, early detection, and personalized treatment strategies based on individual genetic profiles.
• Curso de Posgrado de Alta Especialidad en Medicina Genómica High-specialty postgraduate course in genomic medicine, unique in Mexico, training medical specialists to integrate genomic knowledge into clinical practice.

Quantifiable outcome

• Recognition in Nature Index 2025 for high-impact health sciences research
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• Instituto Mexicano de la Propiedad Industrial (IMPI)coreStrategic or Co-development Partner · 29 May 2026Strategic agreement signed by directors general of both institutions to implement mechanisms enabling the scientific community and underserved sectors to understand and utilize industrial protection tools in health genomics, promoting innovation protection.
• Global Alliance for Genomics and Health (GA4GH)coreStrategic or Co-development Partner · 29 April 2026Strategic alliance making INMEGEN the only Latin American institution with formal collaboration with GA4GH. This partnership positions INMEGEN as the regional leader in genomic standards development and implementation, advancing genomic data sharing and interoperability standards across Latin America.
• Hospital Juárez de MéxicomajorStrategic or Co-development Partner · 7 April 2026Collaborates in the 'Strengthening genomic surveillance of Acinetobacter baumannii in Latin America' project, focusing on monitoring, analysis, and control of antimicrobial-resistant pathogens through advanced genomic tools.
• Universidad de Santiago de Chile (USACH)majorStrategic or Co-development Partner · 7 April 2026Joint project on genomic surveillance of multidrug-resistant bacteria, sharing experiences and best practices with Latin American countries to strengthen regional surveillance capabilities.
• Secretaría de Pueblos y Barrios Originarios y Comunidades Indígenas Residentes (SEPI)coreStrategic or Co-development Partner · 18 July 2022Partnership to extend eVA cancer prevention services to indigenous communities. Addresses the 13% lower access to health services in indigenous populations and provides genetic counseling in indigenous languages.
• Harvard Medical School - Joslin Diabetes CentermajorStrategic or Co-development Partner · 12 May 2021Collaboration on ancient microbiome research published in Nature, reconstructing ancient microbial genomes from human gut samples to understand chronic disease evolution.
• Cámara Nacional de la Industria Farmacéutica (Canifarma), Cofepris, AnafammajorStrategic or Co-development Partner · 12 November 2018Triple helix collaboration agreement for promoting clinical research, involving government regulatory bodies (Cofepris), pharmaceutical industry (Canifarma, Anafam), and academic research (INMEGEN) to advance genomic medicine clinical trials and gene therapy.
• PfizermajorStrategic or Co-development Partner · 24 October 2018Establishment of the Pfizer-INMEGEN Research Chair to strengthen collaborative research and promote scientific work in genomic medicine in Mexico.
• Centro de Estudios en Diabetes A.C.majorStrategic or Co-development Partner · 27 April 2018Collaboration to strengthen scientific knowledge on type 2 diabetes, obesity, and metabolic diseases through a research and development network.
• Petróleos Mexicanos (PEMEX)coreStrategic or Co-development Partner · 28 January 2016General collaboration agreement to develop a genomic medicine platform through scientific and clinical projects. Aims to identify genetic risk and improve medical practice for PEMEX employees and beneficiaries.
• Instituto Nacional de Cancerología (INCAN)coreStrategic or Co-development PartnerCollaborative partnership for cancer prevention through the 'Cuídate y Obsérvate' campaign, combining genomic research capabilities with clinical oncology expertise to reduce cancer incidence and mortality in Mexico.
• Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM)coreStrategic or Co-development PartnerAnnual Día de la Genómica joint conferences focusing on psychiatric diseases, combining genomic and psychiatric research expertise to advance understanding and treatment of mental disorders.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization for molecular biology and genomics in Europe. Comparable to INMEGEN as a publicly funded research consortium advancing genomic science, bioinformatics, and international standards — though at a substantially larger multinational scale.
• National Human Genome Research Institute (NHGRI): The US federal institute dedicated to genomic medicine research, part of NIH. Most directly comparable peer: a publicly funded national institute with a similar mandate to advance genomic science, train researchers, and translate findings into clinical care.
• Garvan Institute of Medical Research: Australian medical research institute with major genomics programs including the Garvan-Weizmann Centre for Cellular Genomics. Comparable in being a national-scale research institute combining clinical genomics, rare disease genetics, and precision medicine.
• Broad Institute of MIT and Harvard: Leading genomic and biomedical research institute. Comparable to INMEGEN in operating at the intersection of population genomics, clinical sequencing, and large-scale computational biology, though with substantially larger scale and funding.
• Wellcome Sanger Institute: UK-based genomic research institute with broad sequencing, bioinformatics, and population genomics capabilities. Comparable to INMEGEN in combining large-scale sequencing infrastructure with population-level genomic research and international standards leadership.
• Beijing Institute of Genomics (Chinese Academy of Sciences): China's national genomics research institute. Comparable in operating as a state-funded national genomics center with population-scale sequencing projects (e.g., Chinese precision medicine initiatives) and large sequencing platform infrastructure.

Emerging players

• Centogene: Commercial genomic diagnostics company focused on rare hereditary diseases, with significant operations in Latin America. Comparable in offering clinical genomic diagnostics and population-level rare disease data, though operating as a private commercial entity versus INMEGEN's public institute model.

Regional players

• Hospital Italiano de Buenos Aires - Genomics Program: Leading Latin American hospital with a significant genomic medicine program (e.g., GCAT-Genomes for Life cohort in Argentina). Most comparable Latin American peer given shared regional focus on Latin American population genomics and similar institutional healthcare setting.
• Genome Institute of Singapore (GIS, A*STAR): Singapore's national genome institute operating population-scale genomic projects and precision medicine programs. Comparable as a publicly funded national genomics institute with focus on population-specific genetic variation and clinical translation.

Broad incumbents

• Mayo Clinic Center for Individualized Medicine: Major US health system's precision medicine program combining genomic diagnostics, clinical interpretation, and research. Comparable in offering integrated genomic medicine services and training programs, though embedded in a much larger private healthcare delivery system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/inmegen
• Facebookfacebook.com/inmegen
• LinkedInlinkedin.com/company/inmegenmx

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto Nacional de Medicina Genómica